AGM
IOVA icon

Alpine Global Management’s Iovance Biotherapeutics IOVA Stock Holding History

Alpine Global Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,106
Closed -$113K – 299
2024
Q2 		$113K Buy
+14,106
New +$151K 0.02% 390
2022
Q1 		– Sell
-35,290
Closed -$674K – 581
2021
Q4 		$674K Buy
+35,290
New +$777K 0.1% 246

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Alpine Global Management's IOVA Position: Q3 2024 in Review

Alpine Global Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 14,106 shares — an estimated $113K sold.

Alpine Global Management first reported a position in IOVA in Q4 2021 and held it in 2 quarters. The position peaked at $674K in Q4 2021. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Alpine Global Management reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 14,106 Iovance Biotherapeutics shares in Q3 2024, an estimated $113K.
  • Alpine Global Management first reported a position in Iovance Biotherapeutics in Q4 2021 and held it in 2 quarters.
  • Alpine Global Management's Iovance Biotherapeutics position peaked at $674K in Q4 2021.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.